FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (IV), its stereoisomer or a pharmaceutically acceptable salt thereof, and its use for the preparation of a medicinal product that activates the GABAA receptor, as well as for the treatment of a disease associated with the central nervous system (CNS) selected from the following group: sleep disorder, mood disorder, schizophrenia spectrum disorder, spasmodic disorder, memory disorder and/or cognitive disorder, dyskinesia, personality disorder, autism spectrum disorder, pain, traumatic brain injury, vascular disease, substance abuse disorder, and/or withdrawal syndrome and tinnitus. In the general formula (IV), Z is selected from the group consisting of -CH2- and -CH2NH-; ring A is selected from the group consisting of a 3–8 membered heterocyclyl containing one or two heteroatoms selected from N and S, phenyl and a 5–10 membered heteroaryl containing one to four heteroatoms selected from N, where each of 3–8 membered heterocyclyl, phenyl and 5–10 membered heteroaryl optionally further substituted with one or more substituents selected from the group consisting of C1-3 alkyl, C1-3 haloalkyl, halogen, oxo, nitro, cyano, methoxy, cyclopropyl, -(CH2)n1SR25, -(CH2)n1C(O)R25 and -(CH2)n1C(O)OR25; each Ra is the same or different and each is selected from the group consisting of hydrogen atom, C1-3 alkyl, C1-3 haloalkyl, methoxy, halogen, nitro, cyano, cyclopropyl, -(CH2)n1C(O)R23, -(CH2)n1C(O)OR23, -(CH2)n1S(O)m1R23 and -(CH2)n1 S(O)(NR23)R24, where each of C1-3 alkyl and cyclopropyl is optionally further substituted with one or more substituents selected from the group consisting of cyano and hydroxy; R15a is selected from the group consisting of C1-3 alkyl, C1-3 haloalkyl, halogen, cyclopropyl, -(CH2)n1OR23 and -(CH2)n1SR23; R16a represents a hydrogen atom; or R15a and R16a may form cyclopropyl, where cyclopropyl is optionally further substituted with one or more halogens; x is an integer equal to either 0, 1, or 3. The remaining values of the variables are indicated in the claims.
EFFECT: creation of new GABAA regulators with good activity and excellent metabolism in vivo.
12 cl, 3 tbl, 179 ex
Title | Year | Author | Number |
---|---|---|---|
REGULATORS OF DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND USE | 2019 |
|
RU2803499C1 |
ORGANIC COMPOUNDS | 2019 |
|
RU2809023C2 |
COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES OF CENTRAL NERVOUS SYSTEM | 2018 |
|
RU2810331C2 |
SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
CHEMICAL COMPOUNDS AND USE THEREOF TO IMPROVE QUALITY OF MUSCLES | 2015 |
|
RU2724329C2 |
COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | 2015 |
|
RU2733756C2 |
STEROIDS THAT RELEASE NITROGEN OXIDE | 2008 |
|
RU2442790C2 |
MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
GLUCOCORTICOIDS CONNECTED BY MEANS OF AROMATIC LINKER IN POSITION 21 TO NITRATE ESTERS, AND THEIR APPLICATION IN OPTHALMOLOGY | 2009 |
|
RU2501804C2 |
Authors
Dates
2023-06-05—Published
2019-01-31—Filed